WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the successful dosing of the first patient in its open-label Phase 1 imaging and dosimetry clinical trial of its uPAR-targeted imaging radiopharmaceutical MNPR-101-Zr. MNPR-101-Zr was well-tolerated with no serious adverse reactions reported through the last imaging timepoint and the corresponding ini ...

Initiated and Enrolling Patients into MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101 radio-immuno-therapeutic (RIT) Clinical Trial on Track to Initiate in Q4 2024 WILMETTE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced second quarter 2024 financial results and summarized recent developments. Recent D ...

WILMETTE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the "Reverse Stock Split"). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Monday August 12, 2024, and its common stock will begin trading on a split-adjusted basis at the ...

Core Viewpoint - Monopar Therapeutics Inc. has initiated its first-in-human Phase 1 clinical trial for MNPR-101-Zr, a novel radiopharmaceutical imaging agent targeting aggressive cancers [1][4]. Group 1: Clinical Trial Details - The Phase 1 trial aims to assess the safety and dosimetry of MNPR-101-Zr in up to 12 patients with advanced cancers [7]. - The trial is led by Professor Rodney Hicks at the Melbourne Theranostic Innovation Centre, marking the first human study evaluating a radiolabeled monoclonal antibody targeting uPAR [7]. - The first patient has been enrolled in the trial, indicating progress in the study [8]. Group 2: Target and Significance - uPAR is identified as a significant target in aggressive cancers such as pancreatic, triple-negative breast, and colorectal cancers [2]. - Encouraging preclinical results have highlighted the potential of uPAR as a promising target for treating lethal cancers [8]. Group 3: Company Overview - Monopar Therapeutics is focused on developing innovative treatments for cancer, including MNPR-101-Zr for imaging and MNPR-101 for radio-immuno-therapeutic applications [4].

Core Insights - Monopar Therapeutics Inc. announced that its abstract on MNPR-101-RIT has been accepted as a "Top-Rated Oral Presentation" at the EANM 2024 Annual Congress, highlighting the company's innovative approach in cancer treatment [1][3] Company Overview - Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing treatments for cancer, including the Phase 1-stage MNPR-101-Zr for imaging and the late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for advanced cancers [4] Product Details - MNPR-101-RIT is a first-in-class radio-immuno-therapeutic targeting cancers with the urokinase plasminogen activator receptor (uPAR), such as triple-negative breast, colorectal, and pancreatic cancers [2] - Preclinical data show significant anti-tumor benefits with MNPR-101 when conjugated to therapeutic radioisotopes like lutetium-177 (Lu-177) and actinium-225 (Ac-225) [2] Clinical Trials - The company has initiated a first-in-human Phase 1 imaging and dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients, with further details available on ClinicalTrials.gov [3]

Core Insights - Monopar Therapeutics Inc. has announced that its abstract on "Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors" has been accepted as a "Top-Rated Oral Presentation" at the EANM 2024 Annual Congress [1][2] - The recognition highlights the potential of Monopar's uPAR-targeted therapy and the growing interest in uPAR as a target for radiopharmaceutical treatments [2] Company Overview - Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative cancer treatments, including the Phase 1 MNPR-101-Zr for imaging advanced cancers and the late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for treating advanced cancers [7] - The MNPR-101-RIT program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), such as triple-negative breast, colorectal, and pancreatic cancers [5] Clinical Trials - Monopar has initiated its first-in-human Phase 1 imaging and dosimetry clinical trial for MNPR-101-Zr in advanced cancer patients, with further details available on ClinicalTrials.gov [6]

WILMETTE, Ill. and Beloit, Wis., June 11, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company, and NorthStar Medical Radioisotopes, LLC, a global innovator in development and commercial production of medical radioisotopes, today announced an amendment and expansion to their existing collaboration. Under terms of the revised collaboration, the Companies entered into a long-term, non-exclusive master supply agreement for NorthStar to provide Monopar with the ...

WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada. SNMMI is the premier educational, scientific, and research event in the radiopharm ...

WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar's Chief Financial Officer, Kim R. Tsuchimoto, will be retiring. Ms. Tsuchimoto will be transitioning over the next month, with her last day being on June 30, 2024. Ms. Tsuchimoto will remain as a member of Monopar's Board of Directors. Mo ...

WILMETTE, Ill., May 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that after a career spanning more than 35 years, Monopar's Chief Financial Officer, Kim R. Tsuchimoto, will be retiring. Ms. Tsuchimoto will be transitioning over the next month, with her last day being on June 30, 2024. Ms. Tsuchimoto will remain as a member of Monopar's Board of Directors. Mo ...